BioCentury | Feb 3, 2021
Finance

Abingworth leans into company creation with largest-ever fund at $465M

...Middle East, Latin America, Africa and Asia. Stephen Hansen Abingworth LLP BEE2021...
BioCentury | Jan 20, 2021
Product Development

Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease

...Golovin Vera Therapeutics Inc. ZymoGenetics Inc. Merck KGaA GV Sofinnova Investments Inc. Longitude Capital Fidelity Management and Research Company Surveyor Capital Octagon Capital Alexandria Venture Investments Abingworth LLP Kleiner...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...Biotech Agent Capital MRL Ventures Fund argenx S.E. Biohaven Pharmaceutical Holding Co. Ltd. Kleo Pharmaceuticals Inc. Yale University OrbiMed Advisors LLC Vivo Capital LLC Abingworth LLP CureVac...
BioCentury | Jan 18, 2020
Politics, Policy & Law

Final reg reduces numbers of biopharma companies subject to CFIUS reviews

...leadership at risk while offering little or no substantive national security benefit.” Consortium members are: Abingworth LLP...
...be deemed foundational or emerging. Steve Usdin, Washingon Editor Versant Ventures Arix Bioscience plc Medicxi Ventures MPM Capital L.P. Sofinnova Partners UCB S.A. Abingworth LLP Biotechnology...
BioCentury | Dec 2, 2019
Financial News

IFM Therapeutics gets $55.5M to launch incubator and new subsidiaries

...containing 3; STING (TMEM173) - Transmembrane protein 173 Val Kennedy, Associate Editor IFM Therapeutics LLC Novartis AG Atlas Venture Omega Funds Abingworth LLP Bristol...
BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...Pharmaceuticals Inc. Verseau Therapeutics Inc. Flagship Pioneering Inozyme Pharma Inc. Theragnostics Ltd. Prescient Medicine Holdings Inc. Orion Biotechnology Canada Ltd. Arrowhead Pharmaceuticals Inc. Abingworth LLP CBC...
BioCentury | Oct 16, 2019
Company News

GammaDelta spins out Adaptate to focus on antibody therapies

...lead target in the next 12-18 months. Elizabeth S. Eaton, Staff Writer GammaDelta Therapeutics Ltd. Takeda Pharmaceutical Co. Ltd. Abingworth LLP Adaptate...
BioCentury | Mar 26, 2019
Company News

Management tracks: Rubius, Abingworth, Arcus

...Inc. CytomX Therapeutics Inc. Forma Therapeutics Inc. Intra-Cellular Therapies Inc. iTeos Therapeutics Inc. Lantheus Holdings Inc. Lantheus Medical Imaging Inc. Rubius Therapeutics Inc. Abingworth LLP Aprea...
BioCentury | Nov 16, 2018
Emerging Company Profile

Virion: Harnessing viral defects

...Warwick Corporate partners: None Number of employees: 8 Funds raised: £13 million ($17 million) Investors: Abingworth LLP...
...Calif. University of Warwick, Coventry, U.K. Virion Biotherapeutics Ltd., London, U.K. Mary Romeo, Staff Writer University of Warwick Abingworth LLP Respiratory...
BioCentury | Jul 13, 2018
Financial News

Abingworth's BioVentures VII fund closes at $315M, exceeding target

...twelfth and leaves it with over $1.2 billion under management. Abingworth Management Ltd., London, U.K. Allison Johnson Abingworth LLP Kurt...
Items per page:
1 - 10 of 14
BioCentury | Feb 3, 2021
Finance

Abingworth leans into company creation with largest-ever fund at $465M

...Middle East, Latin America, Africa and Asia. Stephen Hansen Abingworth LLP BEE2021...
BioCentury | Jan 20, 2021
Product Development

Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease

...Golovin Vera Therapeutics Inc. ZymoGenetics Inc. Merck KGaA GV Sofinnova Investments Inc. Longitude Capital Fidelity Management and Research Company Surveyor Capital Octagon Capital Alexandria Venture Investments Abingworth LLP Kleiner...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...Biotech Agent Capital MRL Ventures Fund argenx S.E. Biohaven Pharmaceutical Holding Co. Ltd. Kleo Pharmaceuticals Inc. Yale University OrbiMed Advisors LLC Vivo Capital LLC Abingworth LLP CureVac...
BioCentury | Jan 18, 2020
Politics, Policy & Law

Final reg reduces numbers of biopharma companies subject to CFIUS reviews

...leadership at risk while offering little or no substantive national security benefit.” Consortium members are: Abingworth LLP...
...be deemed foundational or emerging. Steve Usdin, Washingon Editor Versant Ventures Arix Bioscience plc Medicxi Ventures MPM Capital L.P. Sofinnova Partners UCB S.A. Abingworth LLP Biotechnology...
BioCentury | Dec 2, 2019
Financial News

IFM Therapeutics gets $55.5M to launch incubator and new subsidiaries

...containing 3; STING (TMEM173) - Transmembrane protein 173 Val Kennedy, Associate Editor IFM Therapeutics LLC Novartis AG Atlas Venture Omega Funds Abingworth LLP Bristol...
BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...Pharmaceuticals Inc. Verseau Therapeutics Inc. Flagship Pioneering Inozyme Pharma Inc. Theragnostics Ltd. Prescient Medicine Holdings Inc. Orion Biotechnology Canada Ltd. Arrowhead Pharmaceuticals Inc. Abingworth LLP CBC...
BioCentury | Oct 16, 2019
Company News

GammaDelta spins out Adaptate to focus on antibody therapies

...lead target in the next 12-18 months. Elizabeth S. Eaton, Staff Writer GammaDelta Therapeutics Ltd. Takeda Pharmaceutical Co. Ltd. Abingworth LLP Adaptate...
BioCentury | Mar 26, 2019
Company News

Management tracks: Rubius, Abingworth, Arcus

...Inc. CytomX Therapeutics Inc. Forma Therapeutics Inc. Intra-Cellular Therapies Inc. iTeos Therapeutics Inc. Lantheus Holdings Inc. Lantheus Medical Imaging Inc. Rubius Therapeutics Inc. Abingworth LLP Aprea...
BioCentury | Nov 16, 2018
Emerging Company Profile

Virion: Harnessing viral defects

...Warwick Corporate partners: None Number of employees: 8 Funds raised: £13 million ($17 million) Investors: Abingworth LLP...
...Calif. University of Warwick, Coventry, U.K. Virion Biotherapeutics Ltd., London, U.K. Mary Romeo, Staff Writer University of Warwick Abingworth LLP Respiratory...
BioCentury | Jul 13, 2018
Financial News

Abingworth's BioVentures VII fund closes at $315M, exceeding target

...twelfth and leaves it with over $1.2 billion under management. Abingworth Management Ltd., London, U.K. Allison Johnson Abingworth LLP Kurt...
Items per page:
1 - 10 of 14